Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements

Key Points

• This research aims to analyze the implications of voluntary price agreements on Medicare spending for semaglutide in 2027.
• Compared expected Medicare spending under participation vs nonparticipation in price agreements.
• Estimated the number of beneficiaries who could qualify for expanded obesity-indication coverage.
• Analyzed potential treatment cost offsets linked to agreements.
• Identified significant differences in expected Medicare spending based on price agreement participation.
• Estimated a notable number of beneficiaries eligible for expanded coverage.
• Projected cost savings from voluntary price agreements that could benefit treatment affordability.